Re: Other recent development in ART

[Guest guest]

Dear Dr Swapnil, Thanks for information regarding new ARV drugs. I am also enclosing a link for new antiretroviral drugs. http://www.thebody.com/content/art14919.htmlAnupama--- On Sat, 19/9/09, drswapniljaiswal <drswapniljaiswal@...> wrote:From: drswapniljaiswal <drswapniljaiswal@...>Subject: Other recent development in ARTnetrum@...Date: Saturday, 19 September, 2009, 6:25 AM

Good morning members,

Other new Anti-HIV Agents which are in developmental phases are Attachment inhibitors

Cyanovirin N : Non-specific, block binding of HIV to CD4 during initial entry step. Cyclotriazadisulfon amide: Down regulates expression of CD4 cell Naphthalene sulphonate: Disrupt binding of gp120 to CD4.

HIV Glycoprotien 120 Agents Target first step of entry of HIV in host cell Prevent interaction of CD4 with gp120 SPL 7013: binds HIV gp 120 – microbicide. PRO 542 : completed phase II open label study. Reduce viral load in ART failure patient and ART naïve children

CXCR4 co-receptor antagonist:

POL 3026: Potential for use in combination with CCR5- inhibitors, to prevent selection of CXCR4 population of virus. Regards

Dr. Swapnil Jaiswal.

From cricket scores to your friends. Try the India Homepage!

[Guest guest]

Just as in case of TB we give entire daily dose as a single dose. we can improve the compliance of ART by using following 3 drugs which are given once a dayEmtricitabineEfavirenzAtazanavir(EEA)This is the answer to the quiz question which 3 drugs from different class of anti-HIV drugs are given once a day (EEA)sounds good but treatment cost shoots up with this combination. I am not aware exactly but it can be somewhere between 7 to 10K per month.DR NerurkarFrom: drswapniljaiswal <drswapniljaiswal@ .co. in>Subject: Other recent development in ARTnetrumgroups (DOT) .comDate: Saturday, 19 September, 2009, 6:25 AM

Good morning members,

Other new Anti-HIV Agents which are in developmental phases are Attachment inhibitors

Cyanovirin N : Non-specific, block binding of HIV to CD4 during initial entry step. Cyclotriazadisulfon amide: Down regulates expression of CD4 cell Naphthalene sulphonate: Disrupt binding of gp120 to CD4.

HIV Glycoprotien 120 Agents Target first step of entry of HIV in host cell Prevent interaction of CD4 with gp120 SPL 7013: binds HIV gp 120 – microbicide. PRO 542 : completed phase II open label study. Reduce viral load in ART failure patient and ART naïve children

CXCR4 co-receptor antagonist:

POL 3026: Potential for use in combination with CCR5- inhibitors, to prevent selection of CXCR4 population of virus. Regards

Dr. Swapnil Jaiswal.

From cricket scores to your friends. Try the India Homepage!

From cricket scores to your friends. Try the India Homepage!

[Guest guest]

Just as in case of TB we give entire daily dose as a single dose. we can improve the compliance of ART by using following 3 drugs which are given once a dayEmtricitabineEfavirenzAtazanavir(EEA)This is the answer to the quiz question which 3 drugs from different class of anti-HIV drugs are given once a day (EEA)sounds good but treatment cost shoots up with this combination. I am not aware exactly but it can be somewhere between 7 to 10K per month.DR NerurkarFrom: drswapniljaiswal <drswapniljaiswal@ .co. in>Subject: Other recent development in ARTnetrumgroups (DOT) .comDate: Saturday, 19 September, 2009, 6:25 AM

Good morning members,

Other new Anti-HIV Agents which are in developmental phases are Attachment inhibitors

Cyanovirin N : Non-specific, block binding of HIV to CD4 during initial entry step. Cyclotriazadisulfon amide: Down regulates expression of CD4 cell Naphthalene sulphonate: Disrupt binding of gp120 to CD4.

HIV Glycoprotien 120 Agents Target first step of entry of HIV in host cell Prevent interaction of CD4 with gp120 SPL 7013: binds HIV gp 120 – microbicide. PRO 542 : completed phase II open label study. Reduce viral load in ART failure patient and ART naïve children

CXCR4 co-receptor antagonist:

POL 3026: Potential for use in combination with CCR5- inhibitors, to prevent selection of CXCR4 population of virus. Regards

Dr. Swapnil Jaiswal.

From cricket scores to your friends. Try the India Homepage!

India has a new look. Take a sneak peek.

[Guest guest]

Hello members,

Dr. Nerurkar is absolutely correct. Patient complaince with EEA is good because of single dose, but the cost of treatment is very high. Fantastic information by him. we all expect more from you sir.

Regards

Dr.Swapnil Jaiswal, Junior resident, Pharmacology, GMC Nagpur.

From: drswapniljaiswal <drswapniljaiswal@ .co. in>Subject: Other recent development in ARTnetrumgroups (DOT) .comDate: Saturday, 19 September, 2009, 6:25 AM

Good morning members,

Other new Anti-HIV Agents which are in developmental phases are

Attachment inhibitors

Cyanovirin N :

Non-specific, block binding of HIV to CD4 during initial entry step.

Cyclotriazadisulfon amide:

Down regulates expression of CD4 cell

Naphthalene sulphonate:

Disrupt binding of gp120 to CD4.

HIV Glycoprotien 120 Agents

Target first step of entry of HIV in host cell

Prevent interaction of CD4 with gp120

SPL 7013: binds HIV gp 120 – microbicide.

PRO 542 : completed phase II open label study.

Reduce viral load in ART failure patient and ART naïve children

CXCR4 co-receptor antagonist:

POL 3026:

Potential for use in combination with CCR5- inhibitors, to prevent selection of CXCR4 population of virus.

Regards

Dr. Swapnil Jaiswal.

From cricket scores to your friends. Try the India Homepage!

From cricket scores to your friends. Try the India Homepage!

Add whatever you love to the India homepage. Try now!